VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 336 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2017. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $0 | – | 0 | – | 0.00% | – |
| Q1 2021 | $0 | – | 0 | – | 0.00% | – |
| Q4 2020 | $0 | – | 0 | – | 0.00% | – |
| Q3 2020 | $0 | – | 0 | – | 0.00% | – |
| Q2 2020 | $0 | – | 0 | – | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q2 2018 | $688,000 | +42.1% | 29,618 | +27.2% | 0.03% | +31.8% |
| Q1 2018 | $484,000 | 0.0% | 23,277 | 0.0% | 0.02% | 0.0% |
| Q4 2017 | $484,000 | -73.6% | 23,277 | -81.8% | 0.02% | -69.9% |
| Q3 2017 | $1,836,000 | -17.3% | 128,095 | -0.2% | 0.07% | -22.3% |
| Q2 2017 | $2,220,000 | +57.4% | 128,305 | +0.4% | 0.09% | +54.1% |
| Q1 2017 | $1,410,000 | -16.0% | 127,796 | +10.6% | 0.06% | -24.7% |
| Q4 2016 | $1,678,000 | -60.6% | 115,556 | -33.4% | 0.08% | -63.5% |
| Q3 2016 | $4,262,000 | +22.9% | 173,588 | +0.8% | 0.22% | +14.4% |
| Q2 2016 | $3,467,000 | -77.6% | 172,134 | +12.8% | 0.19% | -81.4% |
| Q4 2015 | $15,509,000 | – | 152,572 | – | 1.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |